
WHO Covid 19 Technology Access Pool

(WHO C-TAP)

Geneva, September 2022



Solidarity Call to Action



To realize equitable global access to COVID-19 health technologies through pooling of knowledge, intellectual property and data.

44 Member States have joined the Solidarity Call to Action so far

Argentina; Bangladesh; Barbados; Belgium; Belize; Bhutan; Bolivia; Brazil; Chile; Costa Rica; Dominican Republic; Ecuador; Egypt; El Salvador; Guatemala; Honduras; Indonesia; Kenya; Lebanon; Luxembourg; Malaysia; Maldives; Mexico; Mongolia; Mozambique; Norway; Oman; Pakistan; Palau; Panama; Paraguay; Peru; Portugal; Saint Vincent and Grenadines; South Africa; Spain; Sri Lanka; Sudan; The Netherlands; Timor-Leste; Tunisia; Turkmenistan; Uruguay; Zimbabwe

Solidarity Call to Action

Governments and health R&D funders: e.g. to take action and promote sharing of IP, Knowledge and data, including through legal and policies measures to facilitate scale up; to include access provisions in funding agreements

Technology holders: e.g. voluntary share their IP, knowledge or data; patent pools

Researchers: e.g. Make information and data available through publicly accessible databases



Solidarity Call to Action

C-TAP objectives and priorities

- Pooling COVID-19 health technologies or products to promote innovation or further development and facilitate scale up production through multiple quality-assured manufacturers that currently have untapped capacity to scale up and diversify production.
- C-TAP's priority in the last two years has been the engagement with technology holders to encourage sharing of intellectual property, know-how or data to promote global equitable access of COVID-19 vaccines, therapeutics, diagnostics or other medical devices.
- While recent licenses indicate the potential of the mechanism to promote access and innovation, significant challenges remain in realizing the full potential of C-TAP.




Share your intellectual property, knowledge or data

Credits




Scope of C-TAP



- Flexible mechanism to negotiate licenses and tech transfer agreements with the support of implementing partners (MPP, Open COVID Pledge, UN Tech Bank)
- Voluntary nature: e.g. Public health-driven voluntary, non-exclusive and transparent licenses.

How C-TAP works to facilitate technology sharing and increase scale up?



Technologies shared through C-TAP: CSIC license

Technology: ELISA antibody technology

Technology holder: Spanish National Research Council (CSIC)

License: Worldwide, non-exclusive and transparent license

C-TAP categorisation after WHO technical pre-assessment: Category III

Description of the technology: The COVID-19 serological antibody technology effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine.

The agreement covers all related patents and the biological material necessary for manufacture of the test.

The licence will be royalty-free for low- and middle-income countries and will remain valid until the date the last patent expires.



United States National Institutes of Health (NIH)



In May 2022, under the auspices of WHO's COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.

The NIH licensing agreements were assessed by the C-TAP Technical Advisory Group (TAG)

Licenses: Worldwide, non-exclusive and transparent

Technologies:

1. Prefusion spike proteins (Vaccine Development)
2. Structure-Based Design of Spike Immunogens (Research Tool for Vaccine Development)
3. Pseudotyping Plasmid (Research Tool for Vaccine Development)
4. ACE2 Dimer construct (Research Tool for Drug Development)
5. Synthetic humanized llama nanobody library and related use Research Tool for Drug and Diagnostic Development)
6. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized Spikes (Vaccine Candidate)
7. Parainfluenza virus 3 based vaccine (Vaccine Candidate)
8. A VSV-EBOV-Based Vaccine (Vaccine Candidate)
9. RNASEH-Assisted Detection Assay for RNA (Diagnostic)
10. Detection of SARS-CoV-2 and other RNA Virus (Diagnostic)
11. High-Throughput Diagnostic Test (Diagnostic)

The NIH logo is displayed in white, bold, sans-serif capital letters on a dark blue, arrow-shaped background pointing to the right.

C-TAP Call to Action

<https://www.who.int/initiatives/covid-19-technology-access-pool/take-action-now>

C-TAP Website :

<https://www.who.int/initiatives/covid-19-technology-access-pool>



Contact details

First name *

Last name *

Type of entity *

- Select an entity type -

Name of entity

Position *

Email *

Address

Country *

City *

Street

PO box

Are you or your Institution the owner of knowledge, intellectual property and/or data necessary for COVID-19 detection, prevention, treatment or response? *

Yes

No

If yes, do you or your Institution own knowledge and/or Intellectual property and/or data?

- Select -

Is your or your Institution's knowledge and/or Intellectual property and/or data necessary for COVID-19 detection, prevention, treatment or response? *

- Select -

Have you already shared or are you considering sharing the aforementioned knowledge, intellectual property and/or data? *

Yes

No

If yes, where have you shared or are you considering sharing the aforementioned knowledge, intellectual property and/or data?

- Select -

Briefly describe the knowledge and/or intellectual property and/or data that you have shared or are considering sharing. *

Do you or your Institution wish to join the Solidarity Call to Action? *

Yes

Unsure

Submit

- **C-TAP prioritization of key products:** treatment guidelines, recommendations, EUL, PQ, etc

- **WHO C-TAP Pre-assessment of technologies:** Vaccines, IVDs, Medical Devices, Therapeutics, Digital platforms

- **C-TAP and implementing partners participate in the negotiations with technology holders**

- **C-TAP contributes in the selection process of quality assured manufacturers for sublicensing**

- **WHO potential support to technology receivers:** regulatory; manufacturing; technology transfer



Pre-Submission Information/screening Information for COVID-19

(For Medical Devices including PPE, Medical & Diagnostics Software, Excluding Digital Healthcare Management Software)


(All submitted information is considered confidential and handled accordingly)

Please refer any question you might have to calltoaction@who.int

Q No	Applicant's Response	
Section 1: Basic details of Contact Person/Applicant		
1.1.	Full Name of Applicant	
1.2.	Full Name of Applicant's Institution	
1.3.	Country	
1.4.	Link to the official website	
1.5.	Email address of the Applicant	
1.6.	Have you submitted your technology for WHO Compendium of Innovative Medical Devices after 2017? <small>Note: 1. If yes, sections 2,5,6, alone can be left empty 2. If previous submission for compendium was at a prototype level, please fill all the sections as well as mention the previous submission details</small>	
1.7.	Year of submission to the Compendium	
1.8.	Title of product in the Compendium	
1.9.	Link to the compendium in which your product was published	

C-TAP to promote further sharing of health technologies

- To move a step forward and overcome the C-TAP challenges in promoting access and innovation realizing the full potential of C-TAP, additional efforts from different stakeholders are needed.
- C-TAP is working identifying ways to stimulate discussion on advancing C-TAP's ability to promote equitable access to COVID-19 health technologies
- We have prepared a questionnaire on incentives for Member States inputs. The questionnaire listed a set of measures that could be implemented by Member States to encourage technology holders to pool technologies through C-TAP.
- Discussion paper on how to promote access provisions in health R&D agreements





WHO Technology Access Pool Database

- WHO has established the Technology Access Pool Database as a tool to provide a global one-stop shop dynamic information source for selected COVID-19 therapeutics, diagnostics, vaccines and other health products.
- The Database includes information related to selected key products:
 - characteristics of the products/technologies,
 - related publications
 - clinical trials
 - the regulatory status information
 - WHO pre-qualification and emergency use listing
 - technology holders and other manufacturers data
 - patent status information and licensing agreements
 - market exclusivities
- With information from several databases: ICTRP; WHO publications COVID-19; Global Observatory on Health R&D; MedsPaL and VaxPal; other sources.
- WIPO has committed some support to C-TAP to find missing information on patent status for certain products
- WHO Member States are contributing with national level information

THANK YOU !